Pharmx Technologies Valuation
| PHX Stock | 0.09 0.01 6.25% |
Pharmx Technologies seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Pharmx Technologies from analyzing the company fundamentals such as Return On Equity of 9.0E-4, operating margin of 0.11 %, and Shares Outstanding of 598.51 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.5575 | Enterprise Value 53.2 M | Enterprise Value Ebitda 36.0181 | Price Sales 6.6562 | Enterprise Value Revenue 7.5936 |
Overvalued
Today
Please note that Pharmx Technologies' price fluctuation is out of control at this time. Calculation of the real value of Pharmx Technologies is based on 3 months time horizon. Increasing Pharmx Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Pharmx Technologies' intrinsic value may or may not be the same as its current market price of 0.09, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.09 | Real 0.0737 | Hype 0.09 | Naive 0.0937 |
The intrinsic value of Pharmx Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pharmx Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pharmx Technologies helps investors to forecast how Pharmx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharmx Technologies more accurately as focusing exclusively on Pharmx Technologies' fundamentals will not take into account other important factors: Pharmx Technologies Cash |
|
Pharmx Technologies Total Value Analysis
Pharmx Technologies is at this time anticipated to have takeover price of 53.16 M with market capitalization of 57.46 M, debt of 13.88 M, and cash on hands of 12.56 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pharmx Technologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
53.16 M | 57.46 M | 13.88 M | 12.56 M |
Pharmx Technologies Investor Information
About 56.0% of the company outstanding shares are owned by corporate insiders. The book value of Pharmx Technologies was at this time reported as 0.03. The company last dividend was issued on the 28th of November 2023. Pharmx Technologies had 1:10 split on the 31st of October 2005. Based on the key indicators related to Pharmx Technologies' liquidity, profitability, solvency, and operating efficiency, Pharmx Technologies is not in a good financial situation at the present time. It has a very high chance of going through financial crunch in August.Pharmx Technologies Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Pharmx implies not a very effective usage of assets in July.Pharmx Technologies Ownership Allocation
Pharmx Technologies owns a total of 598.51 Million outstanding shares. Pharmx Technologies has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pharmx Technologies Profitability Analysis
The company reported the revenue of 6.78 M. Net Loss for the year was (1.77 M) with profit before overhead, payroll, taxes, and interest of 3.96 M.About Pharmx Technologies Valuation
The stock valuation mechanism determines Pharmx Technologies' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pharmx Technologies based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pharmx Technologies. We calculate exposure to Pharmx Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pharmx Technologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5 M | 4.7 M |
Additional Tools for Pharmx Stock Analysis
When running Pharmx Technologies' price analysis, check to measure Pharmx Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmx Technologies is operating at the current time. Most of Pharmx Technologies' value examination focuses on studying past and present price action to predict the probability of Pharmx Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmx Technologies' price. Additionally, you may evaluate how the addition of Pharmx Technologies to your portfolios can decrease your overall portfolio volatility.